Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of HBsAg levels and HBV relapse patterns with HBsAg seroclearance following entecavir or tenofovir cessation.

Biomedical journal·2026
Same author

Risk Group Stratification for True Early Recurrence After Ablation for Hepatomas.

Canadian journal of gastroenterology & hepatology·2026
Same author

Prognostic Significance of Histologic Steatotic Liver Disease in Curatively Resected Non-B, Non-C Hepatocellular Carcinoma.

Cancers·2026
Same author

Sustained virological response improved survival outcomes after curative resection in patients with hepatitis C virus-related hepatocellular carcinoma in the era of direct‑acting antiviral therapy.

Updates in surgery·2026
Same author

Predictive Value of Nutrition Indices in Advanced Hepatocellular Carcinoma Patients Treated With Lenvatinib.

The Kaohsiung journal of medical sciences·2026
Same author

Predictors of True Early Recurrence in Patients Undergoing Radiofrequency Ablation for Hepatocellular Carcinoma.

JGH open : an open access journal of gastroenterology and hepatology·2026

Related Experiment Video

Updated: Jun 12, 2026

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy
10:10

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy

Published on: July 20, 2022

Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: Longitudinal study

Jing-Houng Wang1, Chi-Sin Changchien, Chao-Hung Hung

  • 1Division of Hepato-Gastroenterology, Department of Internal Medicine, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Taiwan.

Journal of Gastroenterology and Hepatology
|June 16, 2010
PubMed
Summary
This summary is machine-generated.

Liver stiffness significantly decreases in sustained responders after interferon-based therapy for chronic hepatitis C virus infection. Factors like advanced fibrosis and higher BMI predict slower improvement in liver stiffness.

More Related Videos

A Three-Dimensional Digital Model for Early Diagnosis of Hepatic Fibrosis Based on Magnetic Resonance Elastography
06:09

A Three-Dimensional Digital Model for Early Diagnosis of Hepatic Fibrosis Based on Magnetic Resonance Elastography

Published on: July 21, 2023

Related Experiment Videos

Last Updated: Jun 12, 2026

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy
10:10

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy

Published on: July 20, 2022

A Three-Dimensional Digital Model for Early Diagnosis of Hepatic Fibrosis Based on Magnetic Resonance Elastography
06:09

A Three-Dimensional Digital Model for Early Diagnosis of Hepatic Fibrosis Based on Magnetic Resonance Elastography

Published on: July 21, 2023

Area of Science:

  • Hepatology
  • Virology
  • Internal Medicine

Background:

  • Chronic hepatitis C virus (HCV) infection can lead to liver fibrosis.
  • Interferon (IFN)-based therapy is a treatment for chronic HCV.
  • Assessing liver stiffness (LS) is crucial for monitoring liver health in HCV patients.

Purpose of the Study:

  • To evaluate changes in liver stiffness (LS) after interferon-based therapy in chronic hepatitis C patients.
  • To identify factors associated with LS changes in patients with sustained virological response (SVR).

Main Methods:

  • Patients with chronic HCV received at least 20 weeks of IFN-based therapy.
  • Liver stiffness was measured using FibroScan at enrollment and after a minimum of 38 weeks.
  • Changes in LS and associated factors were analyzed in sustained virological response (SVR) and non-sustained virological response (NSVR) groups.

Main Results:

  • A significant decrease in LS was observed in SVR patients (P < 0.001), while NSVR patients showed an increase.
  • In SVR patients, high initial LS predicted rapid LS reduction.
  • Advanced fibrosis, higher BMI, and longer remission time predicted slower LS reduction in SVR patients.

Conclusions:

  • Interferon-based therapy leads to decreased liver stiffness in sustained responders with chronic HCV.
  • Predictive factors for slower LS improvement in sustained responders include advanced fibrosis, higher BMI, longer remission, and lower initial LS.